Advancing Off-the-Shelf Immune Tolerance with Allogeneic TR1 Cell Therapies

1:30 pm - Thursday 25th March 2027

  • Showcasing how a non-gene-edited allogeneic TR1 platform is simplifying manufacturing and broadening access to immune tolerance therapies
  • Presenting safety and translational insights challenging historical concerns around allogeneic regulatory cell therapies and GvHD risk
  • Evaluating opportunities for scalable off-the-shelf TR1 therapies to overcome cost, manufacturing, and accessibility barriers across autoimmune disease indications

Speakers:

Chief Technical Officer
TR1X Bio